Before a new medicine is given to a human for the first time, regulators expect a defined set of nonclinical safety data. ICH M3(R2) is the guideline that ties it all together (International Council for Harmonisation [ICH], 2009a). It describes which studies are needed, and when, to support each stage of clinical development.
I studied this framework in the Safety Assessment for First-in-Human Trials and Regulatory Aspects for Approval of Therapeutics modules of my MSc at the University of Basel. This article gives a practical map of what it asks for.
The principle: data must keep pace with exposure
M3(R2) follows one simple logic. The nonclinical data must support the duration, dose and population of the clinical trial being proposed. Longer trials, larger populations and more vulnerable patients need more data (ICH, 2009a).
The guideline aims to protect trial participants while avoiding unnecessary animal use, in line with the 3Rs.
What is typically needed before first-in-human dosing
| Study area | Purpose | Related ICH guideline |
|---|---|---|
| Primary and secondary pharmacology | Understand the intended effect and off-target activity | M3(R2) |
| Safety pharmacology core battery | Assess effects on cardiovascular, central nervous and respiratory systems | S7A, S7B (ICH, 2000, 2005b) |
| Pharmacokinetics and toxicokinetics | Relate toxic effects to exposure | S3A (ICH, 1994) |
| Repeat-dose toxicity, rodent and non-rodent | Identify target organs and a no-observed-adverse-effect level | M3(R2) |
| Genotoxicity (gene mutation assay) | Detect DNA-damaging potential | S2(R1) (ICH, 2011a) |
| Local tolerance | Assess effects at the site of administration | M3(R2) |
The pivotal safety studies are conducted under Good Laboratory Practice (GLP). GLP ensures that study conduct, raw data and reports are traceable and reliable (Organisation for Economic Co-operation and Development [OECD], 1998).
Matching toxicity study duration to clinical duration
Repeat-dose toxicity studies must generally be at least as long as the clinical trial they support. For example, a clinical trial lasting up to two weeks is usually supported by two-week toxicity studies in two species (ICH, 2009a).
For longer development, studies extend up to six months in rodents and nine months in non-rodents, which can support clinical trials of any duration and marketing (ICH, 2009a).
What comes later in development
Some studies are needed only before later phases or before marketing:
- The full genotoxicity battery, usually before phase 2.
- Reproductive and developmental toxicity, timed according to whether women of childbearing potential are included (ICH S5(R3); ICH, 2020).
- Carcinogenicity studies, usually for marketing and only for drugs intended for long-term use (ICH S1A; ICH, 1995).
- Immunotoxicity assessment, following a weight-of-evidence approach (ICH S8; ICH, 2005a).
- Phototoxicity assessment where relevant (ICH S10; ICH, 2013).
Choosing a safe starting dose
The nonclinical package feeds directly into the first human dose. For many small molecules, the starting dose is derived from the NOAEL in the most sensitive species, converted to a human equivalent dose and divided by a safety factor (U.S. Food and Drug Administration [FDA], 2005).
For high-risk molecules, especially immune agonists, developers also calculate the minimal anticipated biological effect level (MABEL). The more conservative approach is generally chosen (European Medicines Agency [EMA], 2017).
Important exceptions and variations
M3(R2) is not one-size-fits-all.
Exploratory clinical trials using very low doses, such as microdose studies, can be supported by a reduced package (ICH, 2009a).
Biotechnology-derived products, such as monoclonal antibodies, follow ICH S6(R1) (ICH, 2011b). Testing is limited to pharmacologically relevant species, and immunogenicity must be considered.
Anticancer pharmaceuticals for patients with advanced cancer follow ICH S9 (ICH, 2009b). The package is streamlined to allow faster access for patients with few options, for example with shorter general toxicity studies before the first trials.
Why understanding the package matters beyond preclinical teams
The nonclinical package is not only relevant to toxicologists. Clinical safety teams use it to define what to monitor in early trials. Regulatory affairs teams present it in Module 4 of the Common Technical Document and defend it in agency discussions.
Later, findings from nonclinical studies may appear in the product information and in the risk management plan as potential risks. A safety scientist who understands where these risks came from can assess post-marketing cases more knowledgeably.
How my background connects
My MSc training covered mechanisms of toxicity, organ-directed toxicity, reproductive toxicology, safety assessment for first-in-human trials and the regulatory aspects of approval. My thesis added practical laboratory experience with in vitro assays relevant to early safety assessment.
Combined with years of practice as a pharmacist, this gives me a view of the whole chain: from the first nonclinical signal to the patient who eventually takes the medicine.
Key takeaways
- ICH M3(R2) links the nonclinical data required to the duration and scope of each clinical stage.
- Safety pharmacology, repeat-dose toxicity in two species and initial genotoxicity are core before first-in-human dosing.
- Biologics (S6) and advanced cancer therapies (S9) follow adapted approaches.
References
European Medicines Agency. (2017). Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1). https://www.ema.europa.eu
International Council for Harmonisation. (1994). Note for guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies S3A. https://www.ich.org
International Council for Harmonisation. (1995). Guideline on the need for carcinogenicity studies of pharmaceuticals S1A. https://www.ich.org
International Council for Harmonisation. (2000). Safety pharmacology studies for human pharmaceuticals S7A. https://www.ich.org
International Council for Harmonisation. (2005a). Immunotoxicity studies for human pharmaceuticals S8. https://www.ich.org
International Council for Harmonisation. (2005b). The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals S7B. https://www.ich.org
International Council for Harmonisation. (2009a). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). https://www.ich.org
International Council for Harmonisation. (2009b). Nonclinical evaluation for anticancer pharmaceuticals S9. https://www.ich.org
International Council for Harmonisation. (2011a). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). https://www.ich.org
International Council for Harmonisation. (2011b). Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1). https://www.ich.org
International Council for Harmonisation. (2013). Photosafety evaluation of pharmaceuticals S10. https://www.ich.org
International Council for Harmonisation. (2020). Detection of reproductive and developmental toxicity for human pharmaceuticals S5(R3). https://www.ich.org
Organisation for Economic Co-operation and Development. (1998). OECD principles on good laboratory practice (OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, No. 1). OECD Publishing.
U.S. Food and Drug Administration. (2005). Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers: Guidance for industry. https://www.fda.gov
Member discussion